Side-effects of resveratrol in HepG2 cells: Reduced pten and increased bcl-xl mRNA expression

Molecular Medicine Reports

Volumn 6, Issue 6, 2012, Pages 1367-1370

  Zheng, Min ^a   Chen, Ruifu ^a   Zhong, Hongyuan ^a   Lin, Qiuyan ^a   Wang, Xiaoqin ^a   Zhao, Zhiwei ^a   Xie, Linna ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Transportation Vocational College   (China)

Author keywords

bcl xl; HepG2; pten; Resveratrol

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL XL; RESVERATROL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-X PROTEIN; CELL PROLIFERATION; HEP G2 CELLS; HUMANS; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; STILBENES;

VITACEAE;

EID: 84868547837     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1077     Document Type: Article

References (30)

1. Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997. (Pubitemid 127696281)
2. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006. (Pubitemid 44136961)
3. Santandreu FM, Valle A, Oliver J and Roca P: Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol Biochem 28: 219-228, 2011.
4. Weng CJ, Wu CF, Huang HW, Wu CH, Ho CT and Yen GC: Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem 58: 2886-2894, 2010.
5. Yan F, Tian XM and Ma XD: Effects of resveratrol on growth inhibition and gap-junctional intercellular communication of HepG2 cells. Nan Fang Yi Ke Da Xue Xue Bao 26: 963-966, 2006 (In Chinese).
6. Ciolino HP, Daschner PJ and Yeh GC: Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58: 5707-5712, 1998. (Pubitemid 29006410)
7. Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR and Zhou XH: Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 380: 644-649, 2009.
8. Lu CC and Chen JK: Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol 223: 343-351, 2010.
9. Yu HB, Zhang HF, Zhang X, et al: Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-κB-mediated mechanism. Hepatogastroenterology 57: 1241-1246, 2010.
10. Parekh P, Motiwale L, Naik N and Rao KV: Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 63: 167-173, 2011.
11. Hiroto Y, Tadokoro K, Tsuda T, et al: Resveratrol, a phytoestrogen found in red wine, down-regulates protein S expression in HepG2 cells. Thromb Res 127: e1-7, 2011.
12. Ma XD, Yan F, Ma AD and Wang HJ: Resveratrol induces HepG2 cell apoptosis by depolarizing mitochondrial membrane. Nan Fang Yi Ke Da Xue Xue Bao 26: 406-408, 413, 2006 (In Chinese).
13. Zhou R, Fukui M, Choi HJ and Zhu BT: Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Br J Pharmacol 158: 462-474, 2009.
14. Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997. (Pubitemid 27147102)
15. Chappell WH, Steelman LS, Long JM, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-164, 2011.
16. Chu EC and Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 10: RA235-241, 2004. (Pubitemid 39424480)
17. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947, 1997. (Pubitemid 27148818)
18. Carracedo A, Alimonti A and Pandolfi PP: PTEN level in tumor suppression: how much is too little? Cancer Res 71: 629-633, 2011.
19. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
20. Castilla C, Congregado B, Chinchon D, Torrubia FJ, Japon MA and Saez C: Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 147: 4960-4967, 2006. (Pubitemid 44402203)
21. Hameed DA, Abdel Raheem AM, Mosad E, Hammouda HM, Kamel NA and Abdel Aziz MA: Bcl-XL and Bcl-2 expression in bilharzial squamous cell carcinoma of the urinary bladder: which protein is prognostic? Urology 72: 374-378, 2008.
22. Watanabe J, Kushihata F, Honda K, et al: Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135: 604-612, 2004. (Pubitemid 38879343)
23. Farina A, Ferranti C and Marra C: An improved synthesis of resveratrol. Nat Prod Res 20: 247-252, 2006. (Pubitemid 43102143)
24. Trantas E, Panopoulos N and Ververidis F: Metabolic engineering of the complete pathway leading to heterologous biosynthesis of various flavonoids and stilbenoids in Saccharomyces cerevisiae. Metab Eng 11: 355-366, 2009.
25. Athar M, Back JH, Tang X, et al: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283, 2007. (Pubitemid 47575677)
26. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL and Rankin GO: Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 136: 2542-2546, 2006. (Pubitemid 44521610)
27. Wenzel E, Soldo T, Erbersdobler H and Somoza V: Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49: 482-494, 2005. (Pubitemid 40780395)
28. Nguyen AV, Martinez M, Stamos MJ, et al: Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 1: 25-37, 2009.
29. Boocock DJ, Faust GE, Patel KR, et al: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252, 2007. (Pubitemid 46984966)
30. Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E and Castanas E: Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest and NOS activation. Biochim Biophys Acta 1760: 1657-1666, 2006. (Pubitemid 44667277)